These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

750 related articles for article (PubMed ID: 28039616)

  • 1. A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK.
    Rinciog C; Watkins M; Chang S; Maher TM; LeReun C; Esser D; Diamantopoulos A
    Pharmacoeconomics; 2017 Apr; 35(4):479-491. PubMed ID: 28039616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis.
    Rogliani P; Calzetta L; Cavalli F; Matera MG; Cazzola M
    Pulm Pharmacol Ther; 2016 Oct; 40():95-103. PubMed ID: 27481628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic Review and Network Meta-analysis of Idiopathic Pulmonary Fibrosis Treatments.
    Fleetwood K; McCool R; Glanville J; Edwards SC; Gsteiger S; Daigl M; Fisher M
    J Manag Care Spec Pharm; 2017 Mar; 23(3-b Suppl):S5-S16. PubMed ID: 28287346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health economic evaluation in idiopathic pulmonary fibrosis in France.
    Porte F; Cottin V; Catella L; Luciani L; Le Lay K; Bénard S
    Curr Med Res Opin; 2018 Oct; 34(10):1731-1740. PubMed ID: 29368948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of idiopathic pulmonary fibrosis: a network meta-analysis.
    Rochwerg B; Neupane B; Zhang Y; Garcia CC; Raghu G; Richeldi L; Brozek J; Beyene J; Schünemann H
    BMC Med; 2016 Feb; 14():18. PubMed ID: 26843176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis.
    Richeldi L; Kolb M; Jouneau S; Wuyts WA; Schinzel B; Stowasser S; Quaresma M; Raghu G
    BMC Pulm Med; 2020 Jan; 20(1):3. PubMed ID: 31914963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.
    Richeldi L; du Bois RM; Raghu G; Azuma A; Brown KK; Costabel U; Cottin V; Flaherty KR; Hansell DM; Inoue Y; Kim DS; Kolb M; Nicholson AG; Noble PW; Selman M; Taniguchi H; Brun M; Le Maulf F; Girard M; Stowasser S; Schlenker-Herceg R; Disse B; Collard HR;
    N Engl J Med; 2014 May; 370(22):2071-82. PubMed ID: 24836310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differing severities of acute exacerbations of idiopathic pulmonary fibrosis (IPF): insights from the INPULSIS® trials.
    Kreuter M; Koegler H; Trampisch M; Geier S; Richeldi L
    Respir Res; 2019 Apr; 20(1):71. PubMed ID: 30971229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nintedanib: A Review of Its Use in Patients with Idiopathic Pulmonary Fibrosis.
    Keating GM
    Drugs; 2015 Jul; 75(10):1131-40. PubMed ID: 26063212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pirfenidone and nintedanib for pulmonary fibrosis in clinical practice: Tolerability and adverse drug reactions.
    Galli JA; Pandya A; Vega-Olivo M; Dass C; Zhao H; Criner GJ
    Respirology; 2017 Aug; 22(6):1171-1178. PubMed ID: 28317233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pirfenidone vs. nintedanib in patients with idiopathic pulmonary fibrosis: a retrospective cohort study.
    Marijic P; Schwarzkopf L; Schwettmann L; Ruhnke T; Trudzinski F; Kreuter M
    Respir Res; 2021 Oct; 22(1):268. PubMed ID: 34666765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subgroup Analysis for Chinese Patients Included in the INPULSIS
    Xu Z; Li H; Wen F; Bai C; Chen P; Fan F; Hu N; Stowasser S; Kang J
    Adv Ther; 2019 Mar; 36(3):621-631. PubMed ID: 30729456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS(®) trials.
    Richeldi L; Cottin V; du Bois RM; Selman M; Kimura T; Bailes Z; Schlenker-Herceg R; Stowasser S; Brown KK
    Respir Med; 2016 Apr; 113():74-9. PubMed ID: 26915984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-Effectiveness Analysis of Nintedanib Versus Pirfenidone in Idiopathic Pulmonary Fibrosis in Belgium.
    Rinciog C; Diamantopoulos A; Gentilini A; Bondue B; Dahlqvist C; Froidure A; Wuyts WA; Soulard S
    Pharmacoecon Open; 2020 Sep; 4(3):449-458. PubMed ID: 31939146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Administration of nintedanib after discontinuation for acute exacerbation of idiopathic pulmonary fibrosis: a case report.
    Ikeda S; Sekine A; Baba T; Yamakawa H; Morita M; Kitamura H; Ogura T
    BMC Pulm Med; 2016 Mar; 16():38. PubMed ID: 26940352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment patterns, healthcare resource utilization, and costs among patients with idiopathic pulmonary fibrosis treated with antifibrotic medications in US-based commercial and Medicare Supplemental claims databases: a retrospective cohort study.
    Corral M; DeYoung K; Kong AM
    BMC Pulm Med; 2020 Jul; 20(1):188. PubMed ID: 32652979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world safety and effectiveness of pirfenidone and nintedanib in the treatment of idiopathic pulmonary fibrosis: a systematic review and meta-analysis.
    Kou M; Jiao Y; Li Z; Wei B; Li Y; Cai Y; Wei W
    Eur J Clin Pharmacol; 2024 Oct; 80(10):1445-1460. PubMed ID: 38963453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effectiveness and cost-effectiveness of treatments for idiopathic pulmonary fibrosis: systematic review, network meta-analysis and health economic evaluation.
    Loveman E; Copley VR; Colquitt JL; Scott DA; Clegg AJ; Jones J; O'Reilly KM; Singh S; Bausewein C; Wells A
    BMC Pharmacol Toxicol; 2014 Nov; 15():63. PubMed ID: 25410822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of the anti-fibrotics for the treatment of idiopathic pulmonary fibrosis in the United States.
    Dempsey TM; Thao V; Moriarty JP; Borah BJ; Limper AH
    BMC Pulm Med; 2022 Jan; 22(1):18. PubMed ID: 35000589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis.
    Corte T; Bonella F; Crestani B; Demedts MG; Richeldi L; Coeck C; Pelling K; Quaresma M; Lasky JA
    Respir Res; 2015 Sep; 16():116. PubMed ID: 26400368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.